Newscast – Page 163 – media

NIH accelerates the development of new cancer immunotherapy strategies for more patients

The National Institutes of Health(NIH) and 11 leading biopharmaceutical companies have launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.
- Source: nih.gov
- 573
- October 16, 2017
Market Views NIH PACT
Durable end to the HIV/AIDS pandemic likely will require an HIV vaccine

Despite remarkable gains in the treatment and prevention of HIV infection, development of an effective HIV vaccine likely will be necessary to achieve a durable end to the HIV/AIDS pandemic, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
- Source: Sciencedaily
- 588
- October 13, 2017
AIDS HIV Researches vaccine
Cholesterol byproduct hijacks immune cells, lets breast cancer spread

High cholesterol levels have been associated with breast cancer spreading to other sites in the body, but doctors and researchers don't know the cause for the link. A new study by University of Illinois researchers found that the culprit is a byproduct of cholesterol metabolism that acts on specific immune cells so that they facilitate the cancer's spread instead of stopping it.
- Source: Medicalxpres
- 741
- October 13, 2017
breast cancer cholesterol metabolism Researches
Respicardia gets FDA approval for remede system to treat sleep apnea

The US Food and Drug Administration (FDA) has approved Respicardia’s transvenous implantable neurostimulation system, remede, for moderate to severe central sleep apnea (CSA) in adults.
- Source: medicaldevice-network
- 547
- October 13, 2017
CSA FDA neurostimulation New Approvals
Pfizer reviewing strategic alternatives for consumer healthcare business

Pfizer Inc. announced that it is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business. Today’s announcement is part of Pfizer’s continuing efforts to allocate resources and capital to best serve patients and maximize value for its shareholders.
- Source: Pfizer
- 555
- October 13, 2017
Company Insight Consumer Healthcare strategic
FDA Grants Priority Review To Gilotrif For Uncommon EGFR Mutations In Advanced NSCLC

Boehringer Ingelheim announced that the supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). The application for Gilotrif is currently under review for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 (L861Q), G719X or S768I substitution mutations as detected by an FDA-approved test.
- Source: careers.biospace
- 572
- October 13, 2017
EGFR New Approvals NSCLC sNDA
ICR researchers demonstrate use of genetic test for prostate cancer therapy

Scientists from the Cancer Biomarkers laboratory team of the Institute of Cancer Research in the UK have carried out research to demonstrate the use of a quick genetic test for the targeted treatment of prostate cancer.
- Source: medicaldevice-network
- 668
- October 12, 2017
cancer genetic prostate Researches
Pfizer unloads Colorado plant as it continues to hive off unwanted Hospira operations

Pfizer has sold another Hospira plant, its second in eight weeks, as it continues to whittle down the unwanted operations it picked up in its $15 billion buyout of the sterile drug manufacturer.
- Source: Fiercepharm
- 536
- October 12, 2017
API Company Insight Hospira
FDA approves LivaNova’s VNS therapy system for epilepsy

UK-based firm LivaNova has obtained approval from the US Food and Drug Administration (FDA) for its new Vagus Nerve Stimulation (VNS) Therapy System designed to treat drug-resistant epilepsy.
- Source: medicaldevice-network
- 850
- October 12, 2017
Company Insight epilepsy New Approvals VNS
Merck buys into KalVista and its DME candidate

Shares in KalVista Pharmaceuticals have surged on news of a deal with Merck & Co potentially worth more than $750 million. Under the deal, Merck, which is known as MSD outside of the US and Canada, is paying KalVista $37 million upfront and taking a 9.9 percent stake in the firm in return for access to its experimental diabetic macular oedema drug KVD001.
- Source: Pharmatime
- 616
- October 12, 2017
diabetic macular Market Views oedema

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.